title: Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG.
abstract: BACKGROUND
  Although bacillus Calmette-Guérin (BCG) has proven highly effective in non-muscle-invasive bladder cancer (NMIBC), but it can cause severe local and systemic side effects.
  
  
  OBJECTIVE
  The objective was to determine whether reducing the dose or duration of BCG was associated with fewer side effects. Efficacy comparisons of one-third dose versus full dose BCG given for 1 yr versus 3 yr have previously been published.
  
  
  METHODS
  After transurethral resection, patients with intermediate- and high-risk NMIBC without carcinoma in situ were randomised to one-third dose or full dose BCG and 1 yr or 3 yr of maintenance.
  
  
  METHODS
  Local and systemic side effects were recorded at every instillation and divided into three time periods: during induction, during the first year after induction, and during the second and third years of maintenance.
  
  
  CONCLUSIONS
  Of the 1316 patients who started BCG, 826 (62.8%) reported local side effects, 403 (30.6%) reported systemic side effects, and 914 (69.5%) reported local or systemic side effects. The percentage of patients with at least one side effect was similar in the four treatment arms (p=0.41), both overall and in the different time periods. The most frequent local and systemic side effects were chemical cystitis in 460 (35.0%) patients and general malaise in 204 patients (15.5%); 103 patients (7.8%) stopped treatment because of side effects. No significant difference was seen between treatment groups (p=0.74). In the 653 patients randomised to 3 yr of BCG, 35 (5.4%) stopped during the first year, and 21 (3.2%) stopped in the second or third year.
  
  
  CONCLUSIONS
  No significant differences in side effects were detected according to dose or duration of BCG treatment in the four arms. Side effects requiring stoppage of treatment were seen more frequently in the first year, so not all patients are able to receive the 1-3 yr of treatment recommended in current guidelines. This study was registered at ClinicalTrials.gov with identifier NCT00002990 (http://clinicaltrials.gov/ct2/show/record/NCT00002990).
authors.affiliation: Department of Urology, New Estense S. Agostino Hospital Ausl Modena, Modena, Italy.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Brausi
authors.forename: Jorg
authors.initials: J
authors.lastname: Oddens
authors.forename: Richard
authors.initials: R
authors.lastname: Sylvester
authors.forename: Aldo
authors.initials: A
authors.lastname: Bono
authors.forename: Cees
authors.initials: C
authors.lastname: van de Beek
authors.forename: George
authors.initials: G
authors.lastname: van Andel
authors.forename: Paolo
authors.initials: P
authors.lastname: Gontero
authors.forename: Levent
authors.initials: L
authors.lastname: Turkeri
authors.forename: Sandrine
authors.initials: S
authors.lastname: Marreaud
authors.forename: Sandra
authors.initials: S
authors.lastname: Collette
authors.forename: Willem
authors.initials: W
authors.lastname: Oosterlinck
mesh_terms: D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging; D018570:Risk Assessment; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D001500:BCG Vaccine
keywords: Dose reduction; Maintenance BCG; Non–muscle-invasive bladder cancer; Side effects; Urothelial carcinoma